Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma.
dc.contributor.author | Ansari, J | en |
dc.contributor.author | Hussain, SA | en |
dc.contributor.author | Ansari, A | en |
dc.contributor.author | Glaholm, J | en |
dc.date.accessioned | 2018-01-22T11:17:27Z | |
dc.date.available | 2018-01-22T11:17:27Z | |
dc.date.issued | 2013 | en |
dc.identifier.issn | 1177-5475 | en |
dc.identifier.uri | http://hdl.handle.net/10026.1/10631 | |
dc.description.abstract |
A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear. | en |
dc.format.extent | 39 - 46 | en |
dc.language | eng | en |
dc.language.iso | eng | en |
dc.subject | clear-cell carcinoma | en |
dc.subject | metastatic RCC | en |
dc.subject | molecular targeted agent | en |
dc.subject | vascular endothelial growth factor receptor inhibitor | en |
dc.title | Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma. | en |
dc.type | Journal Article | |
plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/23467578 | en |
plymouth.volume | 7 | en |
plymouth.publication-status | Published | en |
plymouth.journal | Biologics | en |
dc.identifier.doi | 10.2147/BTT.S25862 | en |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine | |
dc.publisher.place | New Zealand | en |
dc.rights.embargoperiod | Not known | en |
rioxxterms.versionofrecord | 10.2147/BTT.S25862 | en |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | en |
rioxxterms.type | Journal Article/Review | en |